GSK Q3 Core Operating Profit Rises; Reaffirms 2026 Guidance

GSK Q3 Core Operating Profit Rises; Reaffirms 2026 Guidance

GSK (GSK, GSK.L, GS71.DE) reported third-quarter profit before tax of 1.935 billion pounds, compared with 2.456 billion pounds in the prior year. Earnings per share declined to 38.5 pence from 49.9 pence, a year ago. Core operating profit reached 3.076 billion pounds, reflecting a 5% increase year-over-year at CER. Core earnings per share rose 1% at CER to 54.6 pence. Total third quarter sales were 8.9 billion pounds, up 4% AER, or an increase o…

GSK posts Q3 sales of £8.9 billion, up 5%

GSK plc revealed on Wednesday that its turnover stood at £8.9 billion in the third quarter of fiscal 2026, up 5% year over year on a constant exchange rate (CER) basis, exceeding analysts' expectation...

GSK Reports 5% Q3 Sales Growth And Reaffirms 2026 Guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty Medicines. The pharmaceutical group maintained its 2026 guidance, expecting turnover growth of 3% to 5% and core operating profit growth of 7% to 9%.

GSK Analysts See 3.5% Turnover Growth Ahead of Q3 Results

The 15-analyst consensus also projects lower core operating profit and core EPS than a year earlier. GSK is due to release results at 3 a.m. ET Wednesday.